Trial Profile

Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device (DOSED)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OPC 1 (Primary)
Indications Spinal cord injuries
Focus Adverse reactions
Acronyms DOSED
Sponsors Lineage Cell Therapeutics

Most Recent Events

06 Nov 2025 According to Lineage Cell Therapeutics media release, California Institute for Regenerative Medicine (CIRM) continues to review application for a CLIN2 clinical grant to support DOSED study of OPC1.
06 Nov 2025 Results presented in a Lineage Cell Therapeutics media release
04 Aug 2025 According to Lineage Cell Therapeutics media release, the company is currently planning to seek approval from the FDA to introduce its new forthcoming immediate-use thaw-and-inject formulation of OPC1 into the DOSED study

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com